Blog
EQS-News: PALFINGER AG: Challenging Market Conditions Impact HY1 Results; Confident Outlook for HY2/2026
EQS-News: PALFINGER AG: Challenging Market Conditions Impact HY1 Results; Confident Outlook for HY2/2026
SIG Group AG: Strong execution drives solid financial performance
SIG Group AG: Strong execution drives solid financial performance
EQS-News: TeamViewer Q2 2026: DEX turnaround and TeamViewer ONE platform momentum; full-year guidance reaffirmed
EQS-News: TeamViewer Q2 2026: DEX turnaround and TeamViewer ONE platform momentum; full-year guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LR 28 July 2026
Ad hoc announcement pursuant to Art. 53 LR
28 July 2026
Forbo Half-Year Report 2026
Forbo Half-Year Report 2026
EQS-Adhoc: Hypoport SE: Gross profit growth and significant increase in EBIT in H1/26
EQS-Adhoc: Hypoport SE: Gross profit growth and significant increase in EBIT in H1/26
EQS-News: Pentixapharm Completes Capital Increase – New Shares Placed in Full
EQS-News: Pentixapharm Completes Capital Increase – New Shares Placed in Full
EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
EQS-News: Lenzing Group advances strategic transformation
EQS-News: Lenzing Group advances strategic transformation
EQS-Adhoc: Lenzing AG: Lenzing AG advances strategic transformation
EQS-Adhoc: Lenzing AG: Lenzing AG advances strategic transformation
Director/PDMR Shareholding
Director/PDMR Shareholding
EQS-Adhoc: Sirma Group JSC: Transactions in Own Shares under the Share Buyback Program
EQS-Adhoc: Sirma Group JSC: Transactions in Own Shares under the Share Buyback Program
VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission
VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission
EQS-News: Viromed Medical AG: Update on the Planned Acquisition of relyon plasma GmbH
EQS-News: Viromed Medical AG: Update on the Planned Acquisition of relyon plasma GmbH
Form 8.3 - The Vanguard Group, Inc.: DCC plc
Form 8.3 - The Vanguard Group, Inc.: DCC plc
Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Form 8.3 - The Vanguard Group, Inc.: JTC plc
Form 8.3 - The Vanguard Group, Inc.: JTC plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Senior plc
Form 8.3 - The Vanguard Group, Inc.: Senior plc
Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Custodian Property Income REIT plc: Interim dividend
Custodian Property Income REIT plc: Interim dividend
Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Form 8.3 - The Vanguard Group, Inc.: easyJet plc
Form 8.3 - The Vanguard Group, Inc.: easyJet plc
Form 8.3 - The Vanguard Group, Inc.: Rotork plc
Form 8.3 - The Vanguard Group, Inc.: Rotork plc


